Marked Tumor Shrinkage and PSA Biomarker Reductions
Scientific findings presented by Johnson & Johnson at the European Society for Medical Oncology (ESMO) Congress on Saturday delivered compelling validation for novel targeted approaches against refractory oncological malignancies. Evaluating cohorts diagnosed with advanced prostate cancer who had previously exhausted standard systemic regimens, oral candidate JNJ-6143 demonstrated substantial antitumor potency.
Among 31 evaluable participants administered the active 50-milligram daily dosage, 77% experienced a precipitous drop of at least 50% in prostate-specific antigen (PSA) levels, a benchmark blood marker used to monitor systemic disease burden. Furthermore, 48% of treated individuals registered PSA declines exceeding 90%. Crucially, in patients presenting with measurable anatomical lesions on radiographic imaging, 69% achieved confirmed complete or partial tumor regression.
It adds a new mechanism of action to J&J's prostate cancer portfolio.












